leuprolide acetate for depot suspension

P=N/A, N=150, Not yet recruiting, Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine; Reproductive Hospital Affiliated to Jiangxi University of Trad

P3, N=72, Not yet recruiting, Emory University

P4, N=41, Completed, Brigham and Women's Hospital | N=125 --> 41

P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting

Managing Li-Fraumeni syndrome (LFS) and its associated cancers, particularly in young patients, necessitates a comprehensive and multidisciplinary approach. Early genetic testing for TP53 mutations is crucial in identifying LFS, enabling personalized treatment plans and proactive surveillance strategies.

P=N/A, N=40, Recruiting, Consorci Sanitari de Terrassa | Trial primary completion date: Jul 2024 --> Dec 2024

P3, N=504, Active, not recruiting, Alliance Foundation Trials, LLC. | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jul 2025

P2, N=32, Not yet recruiting, OHSU Knight Cancer Institute

P2, N=32, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027

P2; Trial primary completion date: Jun 2024 --> Dec 2024

Se sugiere utilizar bevacizumab u olaparib más bevacizumab en pacientes con CEO estadios III/IV BRCA1/2 negativo o desconocido (HRD positivo) que recibieron quimioterapia basada en platino más bevacizumab y obtuvieron RC/RP...Para pacientes con CEO de alto grado avanzado o metastásico en recaída platino-sensibles se sugiere: • Quimioterapia combinada basada en platino: carboplatino/doxorrubicina liposomal o carboplatino/paclitaxel o carboplatino/ nab-paclitaxel o carboplatino/docetaxel o carboplatino/gemcitabina, por seis ciclos. Si no se tolera la terapia combinada, dar carboplatino o cisplatino solo. • Quimioterapia combinada: carboplatino/gemcitabina o carboplatino/paclitaxel o carboplatino/doxorubicina liposomal, más bevacizumab, seguida de bevacizumab como mantenimiento (hasta progresión o toxicidad)...El paclitaxel semanal o la doxorrubicina liposomal pegilada o el topotecan pueden ser administrados con o sin bevacizumab. • Existen otros agentes que se consideran potencialmente act ivos (capecitabina, ciclofosfamida, ifosfamida, irinotecán, oxaliplatino, pemetrexed, vinorelbina, ciclofosfamida), que se podrían recomendar para líneas posteriores. • Las pacientes con receptores hormonales positivos que no toleran o no tienen respuesta a los regímenes citotóxicos pueden recibir terapia hormonal con tamoxifeno u otros agentes, incluidos los inhibidores de la aromatasa (anastrozol y letrozol) o acetato de leuprolide o acetato de megestrol...El niraparib podría ser útil en pacientes BRCA 1/2 +/-/desconocido, al igual que el rucaparib, sin embargo, este último no tiene aún aprobación del ente regulador en Colombia. Conclusiones: se espera que las recomendaciones emitidas en este consenso contribuyan a mejorar la atención clínica, el impacto oncológico y la calidad de vida de estas mujeres.

P2, N=112, Recruiting, Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center

P3, N=154, Recruiting, Dongkook Pharmaceutical Co., Ltd.

A partial mastectomy and sentinel lymph node biopsy were performed, and the diagnosis was T2 (23 mm), N0 (sn: 0/2), M0: Stage IIA, ER positive, PgR negative, HER2 score 0, Ki-67 index: 25%, Curebest95: H. Leuprorelin was used intermittently for uterine fibroids, but menopause had not occurred, and postoperative drug therapy was continued with tamoxifen (combined with UFT2 for 2 years after surgery) to avoid hair loss...As menopausal status was confirmed, palbociclib was administered in combination with letrozole and the patient is currently under observation. Conclusion During hormone therapy for breast cancer, knee pain is often experienced as an adverse event due to the decrease in estrogen due to aging and joint deformation. In cases such as this case where conservative treatment does not improve the condition and the condition continues for a long time, a detailed examination should be considered with the exclusion of bone metastasis in mind, although this is rare

P2, N=19, Completed, M.D. Anderson Cancer Center | Phase classification: P2a --> P2

P2, N=120, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

P2, N=30, Recruiting, VA Office of Research and Development | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Aug 2027 | Trial primary completion date: Nov 2026 --> May 2027

P3, N=271, Active, not recruiting, Prof. Wolfgang Janni | Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025

P4, N=93, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Jan 2026 | Trial primary completion date: Apr 2024 --> Jan 2025

P2, N=64, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P2, N=19, Active, not recruiting, University of Colorado, Denver | Trial completion date: Apr 2024 --> Apr 2025

P3, N=392, Recruiting, NYU Langone Health

P3, N=2250, Active, not recruiting, Sumitomo Pharma Switzerland GmbH | Trial completion date: Feb 2027 --> Dec 2024 | Trial primary completion date: Feb 2027 --> Dec 2024

Based on the 70-gene assay results from core needle biopsies, high-genomic-risk patients received NCT (anthracycline + cyclophosphamide for 4 cycles, followed by 4 cycles of docetaxel), while low-risk patients underwent 16 weeks of NET with letrozole (±leuprolide for premenopausal women). For ER positive, HER2 negative breast cancer patients initially ineligible for BCS, the use of pre-treatment multi-gene assays to guide selective NCT or NET could substantially increase BCS rates and reduce unnecessary chemotherapy.

P2; Recruiting --> Active, not recruiting

P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024

P3, N=3100, Suspended, Novartis Pharmaceuticals | Recruiting --> Suspended

P2, N=120, Not yet recruiting, Mayo Clinic

P=N/A, N=94, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting

P2, N=257, Completed, Palleos Healthcare GmbH | Active, not recruiting --> Completed

P=N/A, N=42, Active, not recruiting, Medical College of Wisconsin | N=60 --> 42

P2, N=37, Recruiting, Peking University First Hospital

Despite only including AR+ SDC of the parotid, immunoprofiles, such as expression of HER-2, were highly variable, highlighting the potential to tailor systemic regimens based on individual histologic profiles in the future. Studies with larger patient numbers using tumor-specific molecular profiling and tumor heterogeneity analyses are justified to better understand the biology of these tumors. Molecularly informed treatment approaches, including the potential use of AR- and HER-2/Neu-directed therapies upfront in the definitive setting, may hold future promise to further improve outcomes for these patients.

P2, N=0, Withdrawn, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=30 --> 0 | Not yet recruiting --> Withdrawn

Mice in the superovulation (PG) group were administered 7.5 IU of PMSG, followed by the injection of 3.5 μg of GnRHa (Leuprorelin) 48 h later, while mice in the control group (CTR) mated naturally...The transcriptome analysis showed that superphysiological estrogen led to a response of the uterus to a high estrogen signal, resulting in abnormal endometrium and extracellular matrix remodeling and up-regulation of ion transport and inflammation-related genes. Our findings suggest that a combination of PMSG and GnRHa trigger impaired embryo implantation in mice, as the excessive uterine response to superphysiological estrogen levels can lead to the change of gene expression related to endometrial remodeling, abnormal expression of uterine ion transport genes and excessive immune-related genes.

P2, N=88, Recruiting, Fudan University | N=66 --> 88

P1, N=30, Active, not recruiting, Colorado Center for Reproductive Medicine | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024

P3, N=3100, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P3, N=3100, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jul 2028 --> Sep 2029

P4, N=80, Recruiting, Takeda | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> May 2025

P2, N=202, Recruiting, Cancer Research Antwerp | Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025

P2, N=31, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P2a --> P2 | Trial completion date: May 2026 --> Jan 2027 | Trial primary completion date: May 2025 --> Jan 2027